Mallinckrodt Plc Ordinary Share (MNK) 82.30 $MNK
Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Business Wire - Tue Sep 02, 3:10PM CDT
Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. The presentation will include announcement of the company's fiscal year 2015 financial guidance.
Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:00PM CDT
Novo Nordisk (NVO) has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek
Business Wire - Thu Aug 28, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.
Mallinckrodt Nears Buy Point As Sales, Earnings Rise
at Investor's Business Daily - Wed Aug 27, 5:12PM CDT
Drugmaker Mallinckrodt, bulked up by buying Questcor Pharmaceuticals in August and buoyed by its addition to the S&P 500 index, has in the past several months become much more interesting than it used to be. Mallinckrodt's (MNK) earnings fell in 2010...
Mallinckrodt (MNK) On Momo Momentum Watch Today
at The Street - Tue Aug 26, 1:56PM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
Jim Cramer's Top Stock Picks: PLKI MNK
at The Street - Tue Aug 26, 5:00AM CDT
Popeye's Louisiana Kitchen is a quality restaurant stock at a discount while Mallinckrodt Pharmaceuticals has the right formula for growth.
Mallinckrodt to Present at Morgan Stanley 2014 Global Healthcare Conference
Business Wire - Mon Aug 25, 3:05PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, will present at the Morgan Stanley Global Healthcare Conference in New York on Monday, September 8, 2014. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 9:20 AM, Eastern Time.
Investors' Radars Failed to Catch Mallinckrodt (MNK), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 7:49AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Mallinckrodt, the stock of which company has actually seen rising estimates over the past one month.
Lannett Updates on Digoxin Safety Issues, Expands Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:50PM CDT
Lannett Company, Inc.'s (LCI) shares fell after concerns rose regarding the safety of digoxin.
Ampio Shares Fall as STEP Study on Ampion Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:35PM CDT
Shares of Ampio Pharmaceuticals, Inc. (AMPE) declined significantly after the company announced that there will be a delay in the data analysis of the STEP Study on its candidate Ampion.
Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition
Business Wire - Fri Aug 22, 8:00AM CDT
--Ray Furey appointed Senior Vice President and Chief Compliance Officer
How Mallinckrodt (MNK) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:51AM CDT
Mallinckrodt is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Ampio's Ampion Positive in Open Label Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 4:33PM CDT
Ampio Pharmaceuticals, Inc.'s (AMPE) announced positive results from the open label portion of a study on multiple injections of Ampion for osteoarthritis of the knee.
Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York
Business Wire - Tue Sep 02, 3:10PM CDT
Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt's senior management team. The presentation will include announcement of the company's fiscal year 2015 financial guidance.
Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:00PM CDT
Novo Nordisk (NVO) has launched its type II diabetes treatment, Ryzodeg, in Mexico. This makes Mexico the first country where Ryzodeg is commercially available.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Mallinckrodt Pharmaceuticals to Present Data for Investigational and Approved Extended-Release Opioid Combination Medicines at PAINWeek
Business Wire - Thu Aug 28, 8:00AM CDT
Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.
Mallinckrodt Nears Buy Point As Sales, Earnings Rise
at Investor's Business Daily - Wed Aug 27, 5:12PM CDT
Drugmaker Mallinckrodt, bulked up by buying Questcor Pharmaceuticals in August and buoyed by its addition to the S&P 500 index, has in the past several months become much more interesting than it used to be. Mallinckrodt's (MNK) earnings fell in 2010...
Mallinckrodt (MNK) On Momo Momentum Watch Today
at The Street - Tue Aug 26, 1:56PM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
Jim Cramer's Top Stock Picks: PLKI MNK
at The Street - Tue Aug 26, 5:00AM CDT
Popeye's Louisiana Kitchen is a quality restaurant stock at a discount while Mallinckrodt Pharmaceuticals has the right formula for growth.
Mallinckrodt to Present at Morgan Stanley 2014 Global Healthcare Conference
Business Wire - Mon Aug 25, 3:05PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, will present at the Morgan Stanley Global Healthcare Conference in New York on Monday, September 8, 2014. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 9:20 AM, Eastern Time.
Investors' Radars Failed to Catch Mallinckrodt (MNK), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 7:49AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Mallinckrodt, the stock of which company has actually seen rising estimates over the past one month.
Lannett Updates on Digoxin Safety Issues, Expands Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:50PM CDT
Lannett Company, Inc.'s (LCI) shares fell after concerns rose regarding the safety of digoxin.
Ampio Shares Fall as STEP Study on Ampion Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:35PM CDT
Shares of Ampio Pharmaceuticals, Inc. (AMPE) declined significantly after the company announced that there will be a delay in the data analysis of the STEP Study on its candidate Ampion.
Mallinckrodt Announces Key Leadership Appointments Following Completion of Questcor Acquisition
Business Wire - Fri Aug 22, 8:00AM CDT
--Ray Furey appointed Senior Vice President and Chief Compliance Officer
How Mallinckrodt (MNK) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:51AM CDT
Mallinckrodt is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Ampio's Ampion Positive in Open Label Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 4:33PM CDT
Ampio Pharmaceuticals, Inc.'s (AMPE) announced positive results from the open label portion of a study on multiple injections of Ampion for osteoarthritis of the knee.
